Cellvax
About
Cellvax is a French SME specializing in oncology, osteoarthritis, and toxicology. Please find encoded a brief PPT presentation. Founded in 2001, the company was established to address the pressing need for innovative therapies for osteoarthritis—a condition affecting both elderly and younger populations, for which no effective disease-modifying treatment currently exists.
In addition, Cellvax has been actively involved in 12 European collaborative projects. This achievement represents an important milestone in the company’s development and reflects its recognized expertise at the European level.
In this context, I would welcome the opportunity to meet with you to explore potential areas of collaboration, notably for EU grant applications together.
Representatives
CEO
Cellvax